Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1547-1552

  Rogóz, Zofia ^a   Skuza, Grazyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Elevated plus maze test; Fluoxetine; Olanzapine; Rats; Risperidone

Indexed keywords

DIAZEPAM; FLUOXETINE; OLANZAPINE; RISPERIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; MALE; MAZE TEST; MOTOR COORDINATION; NONHUMAN; OPEN FIELD TEST; RAT; ROTAROD TEST; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

EID: 84857489977     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70719-8     Document Type: Article

References (25)

1. Bobo WV, Shelton RC: Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat, 2009, 5, 369-383.
2. Brooke NS, Wiersgalla M, Salzman C: Atypical uses of atypical antipsychotics. Harv Rev Psychiatry, 2005, 13, 317-339. (Pubitemid 43048617)
3. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol, 2001, 16, 197-203. (Pubitemid 32612517)
4. Carlson WH, Kitagawa H: Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull, 2004, 38, 38-45.
5. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
6. Hamner MB: Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry, 1996, 153, 841.
7. Hamner MB, Foldowski RA, Ulmer HC, Frueh BC, Huber MG, Arana GW: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol, 2003, 18, 1-8. (Pubitemid 36127054)
8. Hollander E, Rossi NB, Sood E, Pallanti S: Risperidone augmentation in treatment-resistance obsessivecompulsive disorder: a double-blind, placebo-controlled study. Int J Neuropharmacol, 2003, 6, 397-401. (Pubitemid 38146258)
9. Karl T, Duffy L, O'Brien E, Matsumoto I, Dedova I: Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res, 2006, 171, 286-294. (Pubitemid 43946503)
10. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebocontrolled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
11. Miyamoto J, Tsuji M, Takeda H, Ohzeki M, Nawa H, Matsumiya T: Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm. Eur J Pharmacol, 2004, 504, 97-103. (Pubitemid 39410727)
12. Monnelly EP, Ciraulo DA, Knapp C, Keane T: Lowdose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol, 2003, 23, 193-196. (Pubitemid 36368797)
13. Moore NA, Rees G, Sanger G, Tye NC: Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol, 1994, 5, 196-202. (Pubitemid 24153742)
14. Moore NA, Tye NC, Axton MS, Risius FC: The behavioral pharmacology of olanzapine, a novel"atypical" antipsychotic agent. J Pharmacol Exp Ther, 1992, 262, 545-551.
15. Nowakowska E, Kuś K, Polański A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
16. Partyka A, Jastrzȩbska-Wiȩsek M, Szewczyk B, Stachowicz K, Sławińska A, Poleszak E, Doboszewska U et al.: Anxiolytic-like activity of zinc in rodent tests. Pharmacol Rep, 2011, 63, 1050-1055.
17. Pellow S, File SE: Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav, 1986, 24, 525-529. (Pubitemid 16145187)
18. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC et al: Olanzapine treatment for post-traumatic stress disorder: an open- label study. Int Clin Psychopharmacol, 2001, 16, 331-337. (Pubitemid 33030048)
19. Rogóż Z: Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
20. Rogóż Z: Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep, 2009, 61, 1173-1178.
21. 3 receptor agonist, in rats. Pol J Pharmacol, 2004, 56, 519-526.
22. Saxena S, Wang D, Bystrisky A, Baxter LR, Jr: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry, 1996, 57, 303-306. (Pubitemid 26251110)
23. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 2008, 117, 253-259. (Pubitemid 351350599)
24. Stein DJ, Bouwer C, Hawkridge S, Emsley RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorder. J Clin Psychiatry, 1997, 58, 119-122. (Pubitemid 27149253)
25. Sun T, He W, Hu G, Li M: Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav, 2010, 95, 298-307.